44 results about "Blood Screening" patented technology

The invention discloses a constant temperature synchronous amplified detection method of nucleic acid as well as an application thereof. The method comprises the following steps of: 1) mixing reactants containing the following components: a. a nucleic acid sample under test; b. a primer 1: a 3`-terminal of the primer can be hybridized at a 3`-terminal or near the 3`-terminal of the nucleic acid sample under test, and a 5`-terminal is a promotor sequence; c. a primer 2: the primer can be hybridized with a 5`-terminal of a negative strand of the nucleic acid sample under test; d. one or a plurality of fluorescent probes; e. at least one DNA polymerase relied by RNA; and f. at least one RNA polymerase that can identify the promotor sequence; and 2) carrying out the constant temperature amplification reaction to the mixed reactants in a closed vessel, detecting the changes of fluorescence signals in a reaction system synchronously by a detector, and conducting the quantitative and qualitative detection to the nucleic acid sample according to the time and intensity of fluorescence signal changing. The method and the application have the advantages of low pollution, constant temperature in the reaction process, high detection sensitivity, fast detection speed, low requirements on equipment and instrument and low cost, and are applied to nucleic acid testing in fields such as clinical examination and blood screening.

The invention discloses a method for extracting and purifying target nucleic acid and an application thereof. The extraction method comprises a marker B and a specific conjugate A, wherein, capturing nucleic acid marked by the marker B and target nucleic acid in sample are combined to a solid phase carrier combined with the marker B and the specific conjugate A to form a compound of capturing nucleic acid- target nucleic acid of solid phase carrier-A-B; and the capturing nucleic acid at least comprises a 2`-oxygen-methylation oligoclonal nucleic acid which is specifically combined with the target nucleic acid RNA and is marked by the marker B. The invention also provides a kit for extracting the target nucleic acid, which at least comprises a 2`-oxygen-methylation oligoclonal nucleic acid which is specifically combined with the target nucleic acid RNA and is marked by the marker B, and the 2`- oxygen- methylation oligoclonal nucleic acid is used as the capturing nucleic acid. The method has the advantages of high specificity and purity, less pollution, constant temperature in the reaction process, high sensitivity, fast detecting speed, low requirements on instruments and low cost. Thus, the method is particularly applicable to blood screening.

The invention discloses a nucleic acid aptamer specifically combined with a hepatitis C virus core protein and application thereof. The nucleic acid aptamer is a single stranded DNA shown in a sequence 2 of a sequence table or single stranded DNA containing the nucleic acid aptamer. The nucleic acid aptamer has better affinity with a hepatitis C virus core protein. By using the nucleic acid aptamer disclosed by the invention, the hepatitis C virus core protein in a solution can be captured and can be also detected, and hepatitis C serodiagnosis and blood screening can be realized. Part of thenucleic acid aptamer disclosed by the invention can be used to replace a monoclonal antibody to capture the core protein for hepatitis C detection. The invention has the advantages of high sensitivity, low cost, easiness of preparation and storage, and high application value.

The invention discloses a nucleic acid aptamer of an affinity viral hepatitis C core protein and an application of the nucleic acid aptamer. The nucleic acid aptamer is the following (a) or (b): (a) single-stranded DNA represented by sequence 2 in a sequence table; (b) single-stranded DNA containing the nucleic acid aptamer described in (a). Due to the adoption of the nucleic acid aptamer disclosed by the invention, the viral hepatitis C core protein in a solution can be captured and the viral hepatitis C core protein in a solution can also be detected, which are conductive to hepatitis C serology diagnosis and blood screening. By virtue of the nucleic acid aptamer disclosed by the invention, the monoclonal antibody can be partially replaced to capture core protein for detecting hepatitis C and the nucleic acid aptamer has the advantages of high sensitivity, low cost, and convenience in production and preservation. The nucleic acid aptamer has a relatively high application value.

We describe methods and apparatus for high-speed high-contrast imaging one-, two- and three-dimensional imaging enabled by differential interference contrast time encoded amplified microscopy of transparent media without the need for chemical staining, that are suitable for a broad range of applications from semiconductor process monitoring to blood screening. Our methods and apparatus build on a unique combination of serial time-encoded amplified microscopy (STEAM) and differential interference contrast (DIC) microscopy. These methods and apparatus are ideally suited for identification of rare diseased cells in a large population of healthy cells and have the potential to revolutionize blood analysis and pathology including identification of cancer cells, such as Circulating Tumor Cells (CTC) in early stage disease.

The invention discloses a portable blood safety screening fluoroimmunassay system. The portable blood safety screening fluoroimmunassay system comprises a portable blood fluoroimmunassay device and aportable blood detecting analysis card, wherein the portable blood fluoroimmunassay device is composed of a detecting mechanism, a master control panel, a data storage module and a detecting card trayfor conveying and carrying the portable blood detecting analysis card; the detecting mechanism comprises an alanine aminotransferase detecting module, a fluorescence infectious disease four test module, a blood type detecting module and a hemoglobin detecting module. For meeting the requirements on multiple tests during blood screening joint detection and by matching with a blood screening jointdetecting card, the portable blood safety screening fluoroimmunassay system can rapidly and accurately implement control over detecting reaction conditions and automatically complete interpretation and output of a number of detecting results.

The invention discloses a combined detection card for blood screening, which includes a card base and a card cover fastened on the card base. The card base is provided with a plurality of card slots parallel to each other; the multiple card slots are divided into sequentially Multiple groups are arranged, and each group of card slots corresponds to the infectious disease detection area, blood type detection area, hemoglobin detection area and alanine aminotransferase detection area in sequence, and each card slot is equipped with a test strip matching its detection area; The card cover is sequentially provided with an observation window, a sampling hole and an auxiliary liquid hole at the positions corresponding to the test strips in the infectious disease detection area on the deck; There are sampling holes and auxiliary liquid holes in sequence on the position; the card cover is opened with a sampling hole at the position corresponding to the test strip in the hemoglobin detection area; the card cover is at the position corresponding to the test strip in the alanine aminotransferase detection area There are observation windows and sample injection holes on the top. The invention can realize the detection of multiple items in one card and can ensure the accuracy of detection.

The invention discloses a blood ABD typing rapid comprehensive test card. A card seat (21) of the test card is provided with a plurality of card slots; the plurality of card slots are divided in to a plurality of groups arranged in order; the plurality of card slots are corresponding to a blood group forward typing test region (1), a blood group reverse typing test region (2) and a blood cross-matching test region (3) in sequence; each card slot is provided with a test strip matching the test region thereof; and a card cover is opened with a sampling hole (6) and a flushing hole (7) successively on the positions of each test strip corresponding to the blood group forward typing test region (1), the blood group reverse typing test region (2) and the blood cross-matching test region (3) on the card seat (21). The test card integrates blood group forward typing test, reverse typing test and blood cross-matching test on the same card for simultaneous tests, is short in test time, convenient for carrying, simple in operation, accurate and reliable in results, is suitable for being used in comprehensive tests of primary blood screening and blood group typing, and can also be applied in blood group typing test before transfusion in an emergency military period.

The invention discloses a colorectal cancer judgment model for distinguishing cancer tissue of colorectal cancer from paracancerous normal tissue and an establishing method of the colorectal cancer judgment model. The method includes: selecting 107 genes related to colorectal cancer with methylation differences in the promoter region of the genes; verifying the expression of the 107 genes and the level of methylation in the promoter region by the aid of patients with both methylation and gene expression data in a TCGA (the cancer genome atlas) database, wherein a total of 37 genes are successfully verified, and 371 CpG sites are located in the promoter regions thereof; screening the 371 CpG sites by the aid of the data in the TCGA database, wherein a total of 78 CpG sites is selected; for the 78 CpG sites and on the basis of the data in the TCGA database, establishing the colorectal cancer judgment model by the aid of the elastic network algorithm. With the method, a theoretical basis is provided for blood screening of colorectal cancer in the future.

The invention discloses a real-time fluorescent quantitative PCR (polymerase chain reaction) detection method which can be used for simultaneously performing qualitative and quantitative detection on three genotypes of human parvovirus B19, as well as a universal detection primer, a TaqMan probe and a kit thereof. The universal detection primer and the TaqMan probe disclosed by the invention can be combined with real-time fluorescent quantitative PCR to realize the purpose of accurately, qualitatively and quantitatively detecting B19 virus DNA (deoxyribonucleic acid) of the three genotypes of a sample to be detected, a formed NAT (nucleic acid testing) detection method against the three genotypes of B19 virus on the basis is obviously better than the existing detection technology, and the real-time fluorescent quantitative PCR detection method has the advantages of high accuracy, low pollution, fast detection speed, low requirements on instruments and equipment, low cost and the like; in addition to clinical detection and blood screening, the real-time fluorescent quantitative PCR detection method can also be used for performing qualitative and quantitative analysis on pollution status of the B19 virus in raw material plasma and blood products in scientific research and production and further has important significance in ensuring virus safety of the blood products.

The invention relates to the field of biological medicine, and in particular relates to a gene detection kit for quickly detecting Thailand type alpha-thalassemia in a clinic sample. The technical scheme of the gene detection kit aims at providing the gene detection kit for the Thailand type alpha-thalassemia, wherein the gene detection kit comprises PCR (polymerase chain reaction) liquid, the PCR reaction liquid comprises a forward primer THAI-F and a reverse primer THAI-R, the primers are the forward 10724-10725 position and the reverse 1219-1220 position of the breaking point position aiming at the Thailand type alpha-thalassemia, and the primers are respectively designed at the forward 5'-end and the reverse 3'-end of the breaking point. According to the kit provided by the invention, the leak detection of the alpha-thalassemia caused by the common blood screening method can be reduced, the birth of the children who suffer from the heavy type alpha-thalassemia can be reduced or avoided, and a condition can be created for the more comprehensive thalassemia screening. The detection kit provided by the invention is convenient to use, high in accuracy, and good in social benefit and economic benefit in the high incidence area of the thalassemia.

The invention provides a specific primer and probe for simultaneous detection of HTLV-I and HTLV-II. The probe sequence is 5'-AGTGCCAAAGACCCTTCCTGGGCCTCT-3'. The specific primer is the following sequence or the complementary chain sequence of the following sequence, the upstream primer sequence is 5'-CCTTATATCAGAGGCCGAA-3', and the downstream primer sequence is 5'-TCTGGCAGCCCATTGTCAA-3'. Accordingto the specific primer and the probe, by extracting DNA in a to-be-detected sample and by combining the specific primer and the probe and a real-time fluorescent quantitative PCR detection technique,the purpose that HTLV-I and HTLV-II in the to-be-detected sample are accurately quantification can be achieved; and the infection states of HTLV-I and HTLV-II can be detected simultaneously only through one sample, and the specific primer and the probe are suitable for large-scale blood screening work in both cost and efficiency.

The invention firstly provides a biotin-labeled specific probe which is a biotin-labeled hepatitis c virus probe and has a sequence of biotin-(T)n-TGGTACTGCCTGATAGGGTGCTTGCG, wherein n is the number selected from 3 to 30, preferably 5 to 20. Correspondingly, the invention further provides a viral nucleic acid extraction reagent which comprises the biotin-labeled specific probe. The invention further provides the biotin-labeled hepatitis c virus probe and a biotin-labeled human immunodeficiency virus probe. The viral nucleic acid extraction reagent comprising the three biotin-labeled specific probes can be used for blood screening for three viruses.

The invention relates to the field of virus molecular inspection, and particularly provides a nucleic acid composition and a test kit for blood screening. The nucleic acid composition used in the blood screening provided by the invention comprises a nucleic acid composition for detecting HBV, HCV, HIV and COVID-2019. Researches of the inventor prove that the nucleic acid composition provided by the invention is strong in specificity, high in sensitivity and strong in interference resistance, and can realize rapid detection of HBV/HCV/HIV-1/HIV-2/SARS-Cov-2 in blood screening. Specific double-segment nucleic acid combination design is carried out on HIV-1 and HBV genomes, the situation of missing detection caused by virus gene mutation is greatly reduced, the detection rate is greatly increased, the residual risk of transfusion infection is reduced, screening is carried out on SARS-Cov-2 genomes, and the interference on the detection of HBV and HCV in the combination is obviously reduced. The blood screening detection test kit containing the nucleic acid combination provided by the invention has the advantages of high detection rate, good specificity and strong interference resistance.

The invention discloses an aptamer with affinity to viral hepatitis C core antigen and application thereof. The aptamer provided by the invention is following (a) or (b): single-stranded DNA as shown in sequence 2 of following sequence table (a); single-stranded DNA containing the aptamer described in (a). The aptamer can be used to capture the viral hepatitis C core antigen in a solution and to detect the viral hepatitis C core antigen in the solution, facilitating serological diagnosis and blood screening of viral hepatitis. The aptamer can be used to partially replace a monoclonal antibody, capturing a core antigen to detect viral hepatitis C, and the aptamer has the advantages of high sensitivity, low cost, ease of preparation and ease of storage. The aptamer has high applicable value.

Disclosed are an immunoassay of Plasmodium falciparum for determining the presence/absence of a specific and/or antibody thereof via label in conjugates bound to the specific antigen and/or antibody present in a sample, comprising immobilizing the specific antigen and antibody of Plasmodium falciparum on a solid phase, adding a sample obtained from a subject of interest to the solid phase so as to induce specific antibody-antigen reaction, adding a conjugate of the antigen and a label and a conjugate of the antibody and a label, separately prepared, so as to induce binding of at least one of the conjugates; and an assay device comprising the above-mentioned solid phase and conjugates.

The present invention can effect specific detection of antigens and/or antibodies in patients with manifested malaria-symptoms as well as malaria carriers and can also be efficiently employed in samples at the early stage of malaria infection that is difficult to detect via conventional arts. Further, due to the capacity to utilize sera and blood plasma rather than whole blood, the present invention is well suited to large-scale examination such as blood screening.

The invention discloses a portable type blood fluorescence immunoassay analyzer. The portable type blood fluorescence immunoassay analyzer comprises a detecting mechanism, a master control board, a data storage module and a detecting card tray used for transmitting a platform deck detecting card, wherein the detecting mechanism comprises an alanine aminotransferase detecting module, a fluorescentinfectious disease four-item detecting module, a blood type detecting module and a hemoglobin detecting module. The portable type blood fluorescence immunoassay analyzer is used for multi-item detection which is required in a blood screening joint detecting process, is matched with a blood screening joint detecting card, and can be used for quickly and accurately controlling reaction condition dection and automatically completing judgment and output of multi-item detected results.

The invention relates to an internet-based real-time shared blood screening indoor quality control system and method. The method comprises the following steps: collecting effective and controlled indoor quality control data of a plurality of laboratory reagents of a certain commercial brand and reagent batch numbers and quality control product batch numbers corresponding to the data; grouping thedata according to the reagent batch number and the quality control product batch number; respectively calculating the mean number and the intra-group variance of the detection values of the intra-group quality control products; calculating the total SD; calculating the composition ratio of each group of data volume in the total data; calculating the total average number according to the data volume composition ratio of each group and the respective average number of the weighted sum; setting the quality control limit of the reagent to be +/-2 times of the total average number of total SD, wherein the detection result of the quality control product is in-control within the quality control limit, otherwise, the detection result is out of control. The system and the method provided by the invention can be used for serological detection of infectious disease markers and indoor quality control of nucleic acid detection in blood screening and clinical detection, can provide more accurate judgment results, and realizes real-time online analysis and shared analysis of indoor quality control results in reagent groups.

A method of extracting low-abundance viral nucleic acid is disclosed. The method includes steps of: adding a lysis liquid into blood to release viral nucleic acid into the solution; adding a biotin-labeled specific nucleic acid fragment capable of hybridization with the viral nucleic acid; adding streptavidin-labeled nanometer magnetic beads, wherein streptavidin on surfaces of the magnetic beads can be combined with biotin to form a magnetic bead-streptavidin-biotin-specific nucleic acid fragment-viral nucleic acid composite; and washing the magnetic beads with a washing liquid to remove the viral nucleic acid from the magnetic beads. By adoption of the method, the extraction efficiency and the yield of nucleic acid in low-titer viral samples can be increased so as to reduce false negative detection results due to the low extraction efficiency. The method is particularly suitable for clinic blood screening, and other applications.